An analysis of the measured He-, Ar- and Kr- broadening coefficients γ for 1575 water vapor transitions of 27 vibrational bands belonging to the 0.6-11,200 cm spectral region is performed using an empirical function that contains adjustable parameters. A universal function is detected during the analysis. This function depends on the parameters that are common for all perturbers A = (He, Ar or Kr). A universal function multiplied by one additional parameter x(A) determines the broadening coefficients γ(A) for each perturber A = (He, Ar or Kr).Two fitting procedures are used. The first considers the fit of measured γ(exp) for individual rotational branches while the other considers the global fit of all 1575 measured γ(exp). In the second procedure, ratios of γ(Kr)/γ(He) = 2.543 ± 0.040 and γ(Kr)/γ(Ar) = 1.252 ± 0.036 are found. The coefficients derived from the fitted parameters are compared statistically to measured coefficients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.saa.2020.118883DOI Listing

Publication Analysis

Top Keywords

he- ar-
8
water vapor
8
vapor transitions
8
spectral region
8
broadening coefficients
8
universal function
8
measured γexp
8
coefficients
5
analysis he-
4
ar- kr-broadening
4

Similar Publications

Purpose: This study aimed to assess (1) the prognostic value of circulating tumor DNA (ctDNA) and (2) the ability of ctDNA to detect recurrence compared with standard surveillance in curatively resected early-stage biliary tract cancer (BTC).

Methods: This retrospective, multicenter cohort study evaluated serial ctDNA testing for surveillance in patients with early-stage BTC after curative resection. We evaluated the relapse-free survival (RFS) by ctDNA positivity.

View Article and Find Full Text PDF

This study aims to investigate the effect of Epstein-Barr virus (EBV) reactivation or EBV reactivation with dexamethasone (DXM) in patients with adverse drug reactions (ADRs) through evaluating the levels of monocyte, macrophage M2/M1, and cytokines, and investigating whether expression of EBV receptor EphA2 could specifically influence EBV activation in ADRs. We performed a prospective longitudinal study to analyze the monocytes, macrophages, M2/M1 ratio, and cytokines, including interleukin (IL)-4, IL-13, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IFN-β, C-X-C motif chemokine ligand (CXCL)9, and CXCL10, in patients with maculopapular exanthema (MPE) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), and control groups after disease onset. Skin biopsy samples from these patients were subjected to hematoxylin and eosin (H&E) staining to examine tissue architecture and inflammatory cell infiltration, as well as Epstein-Barr virus-encoded RNA (EBER) staining to detect the presence of EBV within the skin lesions.

View Article and Find Full Text PDF

Background And Aims: Blood-based biomarkers for hepatocellular carcinoma (HCC) and its recurrence are lacking. We previously showed that hepatic γ-hydroxy-1, -propano-2'-deoxyguanosine (γ-OHPdG), an endogenous DNA adduct derived from acrolein by lipid peroxidation, increased during hepatocarcinogenesis. Additionally, higher hepatic γ-OHPdG from HCC patients after surgery were strongly associated with poor survival ( < .

View Article and Find Full Text PDF

Intra-arterial locoregional therapies for intrahepatic cholangiocarcinoma.

Expert Rev Gastroenterol Hepatol

September 2024

Division of Vascular and Interventional Radiology, Department of Radiology, The Georgetown University Medical Center, Washington, DC, USA.

Introduction: Intrahepatic cholangiocarcinoma (ICC) is the 2nd most common primary liver malignancy. For nonsurgical candidates, the primary treatment option is systemic chemotherapy, which can be combined with locoregional therapies to enhance local control. Common intra-arterial locoregional therapies include transarterial hepatic embolization, conventional transarterial chemoembolization, drug-eluting bead transarterial chemoembolization, transarterial radioembolization with Yttrium-90 microspheres, and hepatic artery infusion.

View Article and Find Full Text PDF

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

J Hepatol

July 2024

State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.

Background & Aims: In the global, phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) improved overall survival (OS) vs. sorafenib; durvalumab was non-inferior to sorafenib. HBV is the predominant HCC aetiology in most of Asia vs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!